Core Viewpoint - BioMarin Pharmaceutical Inc. is planning to raise $850 million through the issuance of senior unsecured notes due in 2034 to finance its acquisition of Amicus Therapeutics, Inc. and related expenses [1][3]. Financing Details - The company is launching a $2 billion senior secured term loan "B" facility in addition to an existing $800 million senior secured term loan "A" facility and a $600 million senior secured revolving credit facility to support the acquisition [2]. - The net proceeds from the notes offering, along with borrowings from the term facilities and cash on hand, will be used to fund the acquisition and associated fees [3]. Redemption Conditions - Gross proceeds from the notes will be held in an escrow account until the acquisition is completed, with a mandatory redemption clause if the acquisition is not finalized by December 19, 2026 [4]. Guarantees and Covenants - The notes will be guaranteed by certain subsidiaries of BioMarin, including Amicus post-acquisition, and will include customary covenants that restrict additional debt incurrence and other financial activities [5][6]. Regulatory Information - The notes will not be registered under the Securities Act and will be offered only to qualified institutional buyers or non-U.S. persons, subject to transfer restrictions [7]. Company Overview - BioMarin is a global biotechnology company focused on rare diseases, with a strong portfolio of commercial therapies and a robust pipeline for drug development [9][10].

Core Points - Genmab A/S announced plans to offer $1.5 billion of senior secured notes due 2032 and $1.0 billion of senior unsecured notes due 2033, alongside a new $2.0 billion senior secured term loan "B" facility [1] - The financing is part of the acquisition of Merus N.V., which includes previously syndicated credit facilities totaling $1.5 billion [1] - A preliminary offering memorandum has been provided to potential investors, containing undisclosed information and pro forma financial data related to the acquisition [2] Financial Information - The preliminary offering memorandum includes unaudited pro forma condensed combined financial information for the nine months ended September 30, 2025, and for the year ended December 31, 2024 [2] - Audited consolidated financial statements for the years ended December 31, 2024, 2023, and 2022 are also included, originally prepared in Danish Kroner and retranslated into US Dollars [2]